Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Public ClinicalTrials.gov record NCT01723228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).
Study identification
- NCT ID
- NCT01723228
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 45 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2012 (Type not available)
- Primary completion
- Jan 2015 (Actual)
- Completion
- Jan 2015 (Actual)
- Last update posted
- Nov 9, 2021
2012 – 2015
United States locations
- U.S. sites
- 40
- U.S. states
- 23
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 036 | Birmingham | Alabama | — | — |
| Teva Investigational Site 047 | Sun City | Arizona | — | — |
| Teva Investigational Site 004 | Irvine | California | — | — |
| Teva Investigational Site 016 | La Jolla | California | — | — |
| Teva Investigational Site 042 | Long Beach | California | — | — |
| Teva Investigational Site 041 | San Bernardino | California | — | — |
| Teva Investigational Site 048 | Denver | Colorado | — | — |
| Teva Investigational Site 038 | Englewood | Colorado | — | — |
| Teva Investigational Site 035 | Danbury | Connecticut | — | — |
| Teva Investigational Site 034 | Manchester | Connecticut | — | — |
| Teva Investigational Site 037 | New London | Connecticut | — | — |
| Teva Investigational Site 026 | Washington D.C. | District of Columbia | — | — |
| Teva Investigational Site 015 | Boca Raton | Florida | — | — |
| Teva Investigational Site 021 | Jacksonville | Florida | — | — |
| Teva Investigational Site 033 | Ormond Beach | Florida | — | — |
| Teva Investigational Site 020 | Port Charlotte | Florida | — | — |
| Teva Investigational Site 017 | St. Petersburg | Florida | — | — |
| Teva Investigational Site 019 | Atlanta | Georgia | — | — |
| Teva Investigational Site 003 | Chicago | Illinois | — | — |
| Teva Investigational Site 006 | Chicago | Illinois | — | — |
| Teva Investigational Site 008 | Chicago | Illinois | — | — |
| Teva Investigational Site 025 | Kansas City | Kansas | — | — |
| Teva Investigational Site 009 | Lexington | Kentucky | — | — |
| Teva Investigational Site 046 | Baton Rouge | Louisiana | — | — |
| Teva Investigational Site 024 | Boston | Massachusetts | — | — |
| Teva Investigational Site 031 | Las Vegas | Nevada | — | — |
| Teva Investigational Site 030 | New Brunswick | New Jersey | — | — |
| Teva Investigational Site 014 | Albany | New York | — | — |
| Teva Investigational Site 045 | Commack | New York | — | — |
| Teva Investigational Site 013 | Kingston | New York | — | — |
| Teva Investigational Site 010 | New York | New York | — | — |
| Teva Investigational Site 040 | New York | New York | — | — |
| Teva Investigational Site 022 | Asheville | North Carolina | — | — |
| Teva Investigational Site 005 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 018 | Toledo | Ohio | — | — |
| Teva Investigational Site 028 | Philadelphia | Pennsylvania | — | — |
| Teva Investigational Site 012 | Nashville | Tennessee | — | — |
| Teva Investigational Site 002 | San Antonio | Texas | — | — |
| Teva Investigational Site 011 | Salt Lake City | Utah | — | — |
| Teva Investigational Site 001 | La Crosse | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01723228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01723228 live on ClinicalTrials.gov.